RACK1 and non-small cell lung carcinoma: In this study, we demonstrated that CPNE3 can promote the progression of NSCLC by binding to RACK1 through the VWFA domain and activating the c‐MET signalling pathway, which could be inhibited by using the MET inhibitor JNJ‐38877605.